Replimune (REPL) Stock Gains On Regulatory Update For Lead Therapy
In the most recent trading session, shares of Replimune Group, Inc. (NASDAQ: REPL) saw a significant increase, closing 18.89% higher at $3.335. The increase came after investors responded to the FDA’s Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for Replimune’s lead immunotherapy candidate, RP1 (vusolimogene oderparepvec), in combination with nivolumab for advanced […]